Lantheus Hldg

High-Risk-High-Growth Small Cap Update :)

At $RKLB (+6,12 %) everything is going in the right direction at the moment. Up almost 200% since initial investment about half a year ago. And the future promises much more.

$QBTS (+22,12 %) Although a leading provider of quantum computing is considerably riskier and very far from profitability, it has finally been posting share price gains for a month now and is recovering.

$AWE (+8,43 %) has presented very good figures and is also well equipped for the future. It is a technological niche, but one that it is nevertheless occupying quite successfully.

For more inspiration:

$GRAB (-9,87 %) ,$TMDX (-3,64 %) ,$LNTH (+4,65 %) ,$GRA (+0,85 %) ,$6871 (+0,85 %) ,$4480 (-1,46 %) ,$ACMR (+0,6 %) ,$HIMS (+2,66 %) ,$IONQ ,$ASTS

$PTP (+2,74 %) Pentixapharm,

What exactly is the company that was spun off from Eckert and Ziegler? $EUZ (+9,39 %) was spun off?

Andreas Eckert - founder of Eckert on this:

4 active ingredients including 2 in phase III and 2 in I/IIa

Target 2027 to bring both phase III diagnostics to market with EUR 55m expenditure.

However, further financing measures are required here.

20.8 million shares + 3.9 million in free float.

Other competitors in the market are

Telix Pharma and $TLX (+1,72 %)

Lantheus Holding $LNTH (+4,65 %)

New addition to the depot

$LNTH (+4,65 %)
Lantheus Holdings

EUR 6.59 bn market cap

P/E RATIO 18

2-digit earnings growth forecast for the coming years

Broadly speaking, the company is involved in radiopharmaceutical oncology and precision diagnostics, etc.

The radiopharmaceutical oncology products support medical professionals in detecting, combating and monitoring cancer.

Dis precision diagnostics products help healthcare professionals detect and track diseases at an early stage - when it matters most.

In addition to diagnostic products, there are also therapeutic products and some in the pipeline.

Many of you will come into contact with the products at an older age (although I wouldn't wish it on anyone). Be it because of prostate cancer or to visualize the coronary arteries during a check-up.